Brief: Cellect Biotechnology Announces Positive Outcome From Safety Review Committee

Quoin Pharmaceuticals

12/08/2019 12:44

Aug 12 (Reuters) - Cellect Biotechnology Ltd  APOP.O :
    * CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME FROM
SAFETY
REVIEW COMMITTEE; SUCCESSFULLY TRANSPLANTS 9TH CLINICAL TRIAL
PATIENT
    * CELLECT BIOTECHNOLOGY LTD - EXPECTS TO COMPLETE PATIENT
RECRUITMENT BY END OF 2019 AND RELEASE DATA DURING FIRST HALF OF
2020
    * CELLECT BIOTECHNOLOGY - CO IS GETTING CLOSER TO REALIZING
PLANS
TO INITIATE ITS FIRST TRIAL IN U.S. AS EVIDENCED BY SRC'S RECENT
APPROVAL OF ITS STUDY

Source text for Eikon:  ID:nPn7CN9Gqa 
Further company coverage:  APOP.O 

 ((Reuters.Briefs@thomsonreuters.com;))